Elsevier Introduces Technology Intelligence Solution for Accelerating R&D and Innovation in Europe
News Jan 23, 2009
Elsevier has announced the European availability of illumin8, a Web-based natural language processing solution designed to help corporate research professionals answer complex R&D questions with speed and effectiveness.
illumin8 extracts key relationships across the breadth of Elsevier's premium scientific content, millions of patents and 8 billion Web pages and fuses them into an organized view, making it the richest business search solution in the world, Elsevier claims.
illumin8 searches across a wide range of technical and subject domains, serving the needs of research professionals in a number of different fields such as automotive, oil & gas, electronics, chemicals, coatings and consumer goods and packaging.
illlumin8 optimizes Technology Intelligence and discovery practices, enabling users to comprehend key elements of a technology to efficiently deliver on key strategic initiatives. Because of its algorithms, illumin8 is designed to go beyond simple keyword search and is the only tool that can extract relationships from vast amounts of information. It does so by reading and distilling data for actionable insight, such as accelerating product development innovation, identifying new technologies and finding potential partners/collaborators.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE
Sciformix Corporation Collaborates with Oracle Health SciencesNews
New collaboration enables faster and more informed drug safety decisions.READ MORE